



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL INJECTABLE

Generic	Brand	HICL	GCN	Medi-Span	Exception/Other
TREPROSTINIL SODIUM	REMODULIN, TREPROSTINIL	23650		GPI-14 40170080002080, 40170080002070, 40170080002050, 40170080002060	

GUIDELINES FOR USE

INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW)

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 **AND** meet the following criterion?

- Therapy is prescribed by or in consultation with a cardiologist or pulmonologist

If yes, continue to #2.

If no, do not approve

DENIAL TEXT: See the initial denial text at the end of the guideline

2. Does the patient have documentation (e.g., chart note, lab result, diagnostic test result, etc.) confirming PAH diagnosis based on right heart catheterization with ALL of the following parameters?

- Mean pulmonary artery pressure (PAP) greater than 20 mmHg
- Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
- Pulmonary vascular resistance (PVR) greater than 2 Wood units

If yes, continue to #3.

If no, do not approve

DENIAL TEXT: See the initial denial text at the end of the guideline

3. Is the request for continuation of Remodulin (treprostinil) therapy from a hospital discharge?

If yes, **approve for 12 months by HICL or GPI-14.**

If no, continue to #4.

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL INJECTABLE

INITIAL CRITERIA (CONTINUED)

4. Is the request for a new start of Remodulin (treprostinil) therapy and the patient meets **ONE** of the following criteria?
- The patient is intermediate or high risk
 - The patient had a trial of or contraindication to TWO of the following medications from different drug classes:
 - Oral endothelin receptor antagonist (e.g., Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
 - Oral phosphodiesterase-5 inhibitor (e.g., Revatio [sildenafil], Adcirca [tadalafil])
 - Oral cGMP stimulator (e.g., Adempas [riociguat])

If yes, **approve for 12 months by HICL or GPI-14.**

If no, do not approve.

INITIAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TREPROSTINIL INJECTABLE (Remodulin)** requires the following rule(s) be met for approval:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
- B. Therapy is prescribed by or in consultation with a cardiologist (heart doctor) or pulmonologist (lung/breathing doctor)
- C. There is documentation (such as chart note, lab result, diagnostic test result) showing you have pulmonary arterial hypertension based on all of the following lab values by putting a catheter (narrow flexible tube) into the right side of your heart:
 - 1. Mean pulmonary artery pressure (PAP) greater than 20 mmHg
 - 2. Pulmonary capillary wedge pressure (PCWP) less than or equal to 15 mmHg
 - 3. Pulmonary vascular resistance (PVR) greater than 2 Wood units
- D. **For new start requests of Remodulin (treprostinil), approval also requires ONE of the following:**
 - 1. You are intermediate or high risk
 - 2. You had a trial of or contraindication (harmful for) to TWO of the following medications from different drug classes:
 - a. Oral endothelin receptor antagonist (such as Letairis [ambrisentan], Tracleer [bosentan], Opsumit [macitentan])
 - b. Oral phosphodiesterase-5 inhibitor (such as Revatio [sildenafil], Adcirca [tadalafil])
 - c. Oral cGMP stimulator (such as Adempas [riociguat])
- E. If you are continuing current therapy from a hospital discharge, there is no additional requirement for approval.

(Initial denial text continued on next page)

CONTINUED ON NEXT PAGE



STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES

TREPROSTINIL INJECTABLE

INITIAL CRITERIA (CONTINUED)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

RENEWAL CRITERIA

1. Does the patient have a diagnosis of pulmonary arterial hypertension (PAH) World Health Organization (WHO) Group 1 and meet **ONE** of the following criteria?
 - The patient has shown improvement from baseline in the 6-minute walk distance test
 - The patient remains stable from baseline in the 6-minute walk distance test AND the patient's World Health Organization (WHO) functional class have improved or remained stable

If yes, **approve for 12 months by HICL or GPI-14.**

If no, do not approve.

RENEWAL DENIAL TEXT: *Some terms are already pre-defined in parenthesis. Please use these definitions if the particular text you need to use does not already have definition(s) in it.

Our guideline named **TREPROSTINIL INJECTABLE (Remodulin)** requires the following rule(s) be met for renewal:

- A. You have pulmonary arterial hypertension (PAH: type of high blood pressure that affects arteries in the lungs and in the heart) World Health Organization (WHO Group 1: a way to classify the severity of disease)
- B. You meet ONE of the following:
 1. You have shown improvement from baseline in the 6-minute walk distance test
 2. You remain stable from baseline in the 6-minute walk distance test with an improved or stable World Health Organization functional class (WHO-FC: classification system for heart failure)

Your doctor told us [INSERT PT SPECIFIC INFO PROVIDED]. We do not have information showing you [INSERT UNMET CRITERIA]. This is why your request is denied. Please work with your doctor to use a different medication or get us more information if it will allow us to approve this request.

CONTINUED ON NEXT PAGE



**STANDARD COMMERCIAL DRUG FORMULARY
PRIOR AUTHORIZATION GUIDELINES**

TREPROSTINIL INJECTABLE

RATIONALE

For further information, please refer to the Prescribing Information and/or Drug Monograph for Remodulin.

REFERENCES

- Remodulin [Prescribing Information]. Research Triangle Park, NC; United Therapeutics Corp., July 2021.

Library	Commercial	NSA
Yes	Yes	No

Part D Effective: N/A

Commercial Effective: 07/01/23

Created: 03/23

Client Approval: 05/23

P&T Approval: 04/23